The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. The world's largest and longest ...

A rigorous study that randomly assigned Parkinson’s patients to take exenatide, a relative of Ozempic, showed absolutely no benefit or slowing of the course of the degenerative disease after 96 ...

A phase 3 randomized controlled trial found no significant improvements with the GLP-1 exenatide in this population. Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo ...

Demi Moore laid down the law on how to pronounce her name — and it turns out fans have had it wrong this whole time. The movie star, 62, addressed the name debacle during an appearance on ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

It was announced today that the weatherfront set to batter the UK on Friday, January 25, has been named Storm Éowyn. While most people will be concerned with the disruption it will cause, others ...

(HealthDay News) — The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson’s disease severity, according to a study published online Feb. 4 in The ...

FRIDAY, Feb. 7, 2025 (HealthDay News) -- The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, according to a study published ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s disease, finds a new study led by UCL researchers. The world’s largest and ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s disease, finds a new study led by UCL Queen Square Institute of Neurology ...